4 months ago
24
JCDD, Vol. 11, Pages 205: Association of Abnormal Cardiac Biomarkers and Cardiovascular Complications, with Mortality in Patients with SARS-CoV-2 Infection in Latin America
Journal of Cardiovascular Development and Disease doi: 10.3390/jcdd11070205
Authors: Juan Esteban Gómez-Mesa Manuela Escalante Juan Andrés Muñoz-Ordoñez Valeria Azcárate-Rodriguez Juan David Peláez-Martínez Andrea Alejandra Arteaga-Tobar Hoover León-Giraldo Andrea Valencia-Orozco Eduardo Roque Perna Alexander Romero Iván Mendoza Fernando Wyss José Luis Barisani Mario Speranza Walter Alarco Cesar Herrera Julián Lugo-Peña Liliana Patricia Cárdenas-Aldaz Victor Rossel Daniel Sierra
Background: The COVID-19 pandemic has highlighted a correlation between cardiac complications and elevated cardiac biomarkers, which are linked to poorer clinical outcomes. Objective: This study aims to determine the clinical impact of cardiac biomarkers in COVID-19 patients in Latin America. Subjects and methods: The CARDIO COVID 19-20 Registry is a multicenter observational study across 44 hospitals in Latin America and the Caribbean. It included hospitalized COVID-19 patients (n = 476) who underwent troponin, natriuretic peptide, and D-dimer tests. Patients were grouped based on the number of positive biomarkers. Results: Among the 476 patients tested, 139 had one positive biomarker (Group C), 190 had two (Group B), 118 had three (Group A), and 29 had none (Group D). A directly proportional relationship was observed between the number of positive biomarkers and the incidence of decompensated heart failure. Similarly, there was a proportional relationship between the number of positive biomarkers and increased mortality. In Group B, patients with elevated troponin and natriuretic peptide and those with elevated troponin and D-dimer had 1.4 and 1.5 times higher mortality, respectively, than those with elevated natriuretic peptide and D-dimer. Conclusions: In Latin American COVID-19 patients, a higher number of positive cardiac biomarkers is associated with increased cardiovascular complications and mortality. These findings suggest that cardiac biomarkers should be utilized to guide acute-phase treatment strategies.
